The blood-brain barrier is traditionally regarded as an insurmountable obstacle to the effective drug therapy of brain metastases from solid tumors. Here we describe a striking case of complete radiologic response to chemotherapy, and propose that the critical success factors include the large tumor size, HER2-positivity, and concomitant use of trastuzumab.
Introduction
Oncology practice guidelines teach that neither cytotoxic therapy nor large-molecule target-specific therapies are routinely useful in treating cerebral metastases [1, 2] unless these arise from exquisitely chemosensitive primary tumors such as lymphomas or germ-cell neoplasms [3] . To address this unmet need, cerebral metastasectomy and/or sterotactic radiotherapy have become standards of care for most solid tumor patients with intracranial and limited extracranial metastatic disease [4] , reflecting perceptions of a blood-brain barrier (BBB) that hinders transmembrane passage of drug molecules larger than 400 Da [5] .
In recent years this orthodoxy has been challenged on empirical and theoretical grounds [6] , with one objection being that the BBB is disrupted by intracerebral deposits larger than 1 cm [7] . HER2-overexpressing breast cancers are relevant to this debate, given that they recur preferentially within the brain [8] , presumably reflecting the rich supply of HER-stimulatory heregulin ligands (neuregulins) [9] within the metastatic 'soil' of the central nervous system [10] . Relevant to this debate, we report here the history of a 50-year-old woman who presented with aggressive metastatic HER2+ breast cancer that required immediate upfront systemic therapy.
Case Report
A 50-year-old female presented in July 2012 after noticing thickening in the lateral aspect of the right breast. Core biopsy confirmed a 20 mm hormone receptor-negative grade 2 invasive ductal carcinoma with high levels of HER2 by both immunohistochemistry and in-situ hybridization. The patient reported no symptoms of metastatic disease, including no headaches or focal symptoms. Examination demonstrated a palpable breast mass with matted axillary lymph nodes, and normal neurological status. PET/CT scan demonstrated FDG-avid metastases in the right breast, right axillary lymph nodes, and multiple bilateral pulmonary nodules; in addition, however, a large photopenic and hypoattenuating area was detected in the right frontal lobe. CT-guided biopsy of a pulmonary nodule confirmed adenocarcinoma. Brain MRI confirmed two frontal lobe lesions ( Fig. 1 ) (upper panels), the largest 28 mm, with extensive surrounding oedema. Gamma-knife surgery was deemed unfeasible due, but this was deemed unfeasible due to the size of the two lesions. Treatment was commenced using dexamethasone for cerebral oedema and 3-weekly standard chemotherapy using docetaxel/carboplatin plus trastuzumab (Herceptin™; DCH) with pegfilgrastim support. Repeat CT scan prior to the second cycle of DCH revealed a partial response, while a repeat MRI after five cycles showed a complete response (Fig. 1) . There was also a clinical remission of the breast mass, a radiologic complete remission of the axillary adenopathy, plus near-complete remission of the pulmonary metastases. The patient continues on trastuzumab. 
Discussion
Complete responses of brain metastases to systemic therapies have been reported for kinase inhibitor therapy of lung cancer [11] ; for cytotoxic chemotherapy of germ-cell tumors [12] ; and in breast cancer, for hormonal therapy [13] , concurrent chemoradiation plus lapatinib [14] , and (for small brain secondaries only) oral capecitabine [15] . In addition, responses of leptomeningeal breast cancer have been reported using intrathecal trastuzumab [16] . Partial responses of intracerebral metastases are reported in pretreated patients receiving tamoxifen [17] , trastuzumab-radiation [18] , trastuzumab-cytotoxic combinations [19] , and capecitabine-lapatinib [20] . These testimonials to drug efficacy suggest that the traditional notion of the blood-brain barrier may be declining in relevance to the management of brain metastasis.
Trastuzumab reportedly exhibits poor penetration into the brain [21] , and is widely believed to be ineffective in controlling brain metastases in breast cancer patients [22] . Despite this, trastuzumab induces radiosensitization in the context of cerebral metastases [23] , and patients with HER2-positive brain metastases who continue trastuzumab experience longer survival [24, 25] . In contrast, the anticipated efficacy of the small-molecule HER2 kinase inhibitor lapatinib as single-agent therapy for brain metastases has proven to be marginal [26] . Indeed, based on published reports, we can infer no inverse relationship between drug molecular weight (Table 1 ) and clinical efficacy of brain metastasis therapy in breast cancer patients.
In summary, just as there is growing enthusiasm for first-line use of HER2 inhibitors in lieu of chemotherapy for early breast cancer [27] , so does the present case suggest that trastuzumab-based chemotherapy could come to displace surgery and/or radiation therapy in selected cases of HER2-positive bulky brain metastases. Accordingly, in this palliative context, we submit that chemonaive HER2-positive intracerebral disease should now join lymphomas and germ-cell tumors in the category of "highly chemosensitive tumors" [3] . 
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